{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T23:02:40Z","timestamp":1648681360664},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/jcn.0b013e3181f1e3bd","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T01:56:52Z","timestamp":1372903012000},"page":"239-249","source":"Crossref","is-referenced-by-count":0,"title":["Antiplatelet Therapy in Acute Coronary Syndromes"],"prefix":"10.1097","volume":"26","author":[{"given":"Kathy","family":"Berra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Handberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210128","first-page":"e148","article-title":"ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non-st-elevation myocardial infarction: executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction).","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"R2-12-20210128","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIRCULATIONAHA.106.179918","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.","volume":"115","author":"Rosamond","year":"2007","journal-title":"Circulation"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/archinte.167.22.2405","article-title":"Symptom presentation of women with acute coronary syndromes.","volume":"167","author":"Canto","year":"2007","journal-title":"Arch Intern Med"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archinternmed.2009.50","article-title":"Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease. A report from the Women's Ischemia Syndrome Evaluation study and the St James Women Take Heart Project.","volume":"169","author":"Gulati","year":"2009","journal-title":"Arch Intern Med"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"R7-12-20210128","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1161\/CIRCULATIONAHA.105.537878","article-title":"Pathophysiology of coronary artery disease.","volume":"111","author":"Libby","year":"2005","journal-title":"Circulation"},{"key":"R8-12-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/heart.83.3.361","article-title":"The pathophysiology of acute coronary syndromes.","volume":"83","author":"Davies","year":"2000","journal-title":"Heart"},{"issue":"12A","key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"3H","DOI":"10.1016\/S0002-9149(03)00428-4","article-title":"Prothrombotic and antithrombotic pathways in acute coronary syndromes.","volume":"91","author":"Selwyn","year":"2003","journal-title":"Am J Cardiol"},{"key":"R10-12-20210128","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low dose aspirin for the prevention of atherothrombosis.","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-12-20210128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/10903120190940353","article-title":"Turtle Creek Conference II. Acute coronary syndrome: pharmacotherapy.","volume":"5","author":"O'Connor","year":"2001","journal-title":"Prehosp Emerg Care"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.292.15.1867","article-title":"Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.","volume":"292","author":"Tran","year":"2004","journal-title":"JAMA"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","article-title":"Aspirin for the prevention of cardiovascular disease. US Preventive Services Task Force recommendation statement.","volume":"150","year":"2009","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"R15-12-20210128","first-page":"S72","article-title":"American Diabetes Association. Aspirin therapy in diabetes.","volume":"27","author":"Colwell","year":"2004","journal-title":"Diabetes Care"},{"key":"R16-12-20210128","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/heart.85.3.265","article-title":"Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.","volume":"85","author":"Sanmuganathan","year":"2001","journal-title":"Heart"},{"key":"R18-12-20210128","first-page":"185","article-title":"GISSI-3 Investigators. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial.","volume":"2","author":"Latini","year":"2000","journal-title":"Heart Dis"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1161\/CIRCULATIONAHA.106.629212","article-title":"Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis.","volume":"113","author":"Jhund","year":"2006","journal-title":"Circulation"},{"key":"R20-12-20210128","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task force on clinical expert consensus documents.","volume":"118","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"501","DOI":"10.5694\/j.1326-5377.2006.tb00665.x","article-title":"Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review.","volume":"185","author":"Schaffer","year":"2006","journal-title":"Med J Aus"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.amjcard.2005.01.049","article-title":"Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.","volume":"95","author":"Serebruany","year":"2005","journal-title":"Am J Cardiol"},{"key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/eurheartj\/ehi684","article-title":"Aspirin and clopidogrel resistance: an emerging clinical entity.","volume":"27","author":"Wang","year":"2006","journal-title":"Eur Heart J"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1161\/01.CIR.92.9.2432","article-title":"Cigarette smoking acutely increases platelet thrombosis formation in patients with coronary artery disease taking aspirin.","volume":"92","author":"Hung","year":"1995","journal-title":"Circulation"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjcard.2004.12.038","article-title":"Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction.","volume":"95","author":"Schwartz","year":"2005","journal-title":"Am J Cardiol"},{"key":"R27-12-20210128","first-page":"1220","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.","volume":"1215-","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"R28-12-20210128","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.","volume":"321","author":"Hass","year":"1989","journal-title":"N Engl J Med"},{"key":"R32-12-20210128","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","article-title":"Gershlick AH, for the CLASSICS investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS).","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"R33-12-20210128","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial.","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"R34-12-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1067\/mhj.2000.108239","article-title":"Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin, CAPRIE investigators.","volume":"140","author":"Bhatt","year":"2000","journal-title":"Am Heart J"},{"key":"R35-12-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.amjcard.2006.03.062","article-title":"TIMI Study Group. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28).","volume":"98","author":"Gibson","year":"2006","journal-title":"Am J Cardiol"},{"key":"R36-12-20210128","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial.","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"R37-12-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"R38-12-20210128","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"9694","key":"R39-12-20210128","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials.","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"key":"R41-12-20210128","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","article-title":"Frelinger AL, et al, for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"R43-12-20210128","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3949\/ccjm.77a.09173","article-title":"Omeprazole and clopidogrel: should clinicians be worried?","volume":"77","author":"Depta","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"R44-12-20210128","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R45-12-20210128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","article-title":"2009 focused updates: ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC\/AHA\/SCAI guideline on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update), a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"120","author":"Kushner","year":"2009","journal-title":"Circulation"},{"key":"R47-12-20210128","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1161\/01.CIR.101.22.2557","article-title":"Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.","volume":"101","author":"Boersma","year":"2000","journal-title":"Circulation"},{"key":"R48-12-20210128","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2007.01.003","article-title":"Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.","volume":"49","author":"Grines","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R51-12-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"R55-12-20210128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty.","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"R56-12-20210128","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1161\/01.CIR.96.5.1488","article-title":"Effect of Ca2+ on GP IIb\/IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.","volume":"96","author":"Phillips","year":"1997","journal-title":"Circulation"},{"key":"R58-12-20210128","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R59-12-20210128","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Enhanced Suppression of the Platelet IIb\/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"R60-12-20210128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ccd.10392","article-title":"Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension.","volume":"58","author":"Rezkalla","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"R61-12-20210128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication.","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"R63-12-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1472-6963-7-55","article-title":"Patient adherence to medical treatment: a review of reviews.","volume":"7","author":"Dulmen","year":"2007","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"R64-12-20210128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4037\/ccn2010384","article-title":"Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.","volume":"30","author":"Fletcher","year":"2010","journal-title":"Crit Care Nurse"},{"issue":"17","key":"R65-12-20210128","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"R66-12-20210128","first-page":"60","article-title":"The novel anticoagulants, entering a new era.","volume":"139","author":"Bounameaux","year":"2009","journal-title":"Swiss Med Wkly"}],"container-title":["Journal of Cardiovascular Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCN.0b013e3181f1e3bd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:43:56Z","timestamp":1620956636000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005082-201105000-00012"}},"subtitle":["Implications for Nursing Practice"],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcn.0b013e3181f1e3bd","relation":{},"ISSN":["0889-4655"],"issn-type":[{"value":"0889-4655","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}